Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan L Roth

Showing results (31-40 of 450) with videos related to

Pageof 45
Sort By:
Molecular Pharmacology|December 4, 2003
Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variantsVincent Setola, Bryan L Roth
The International Journal of Neuropsychopharmacology|December 19, 2014
DREADD: a chemogenetic GPCR signaling platformHu Zhu, Bryan L Roth
Biochemistry|September 5, 2018
Phosphoproteomics Illuminates Opioid ActionsTao Che, Bryan L Roth
Neuron|May 24, 2014
Silencing synapses with DREADDsHu Zhu, Bryan L Roth
Molecular Interventions|October 13, 2006
Salvinorin A: from natural product to human therapeuticsTimothy A Vortherms, Bryan L Roth
Nature Chemistry|January 5, 2024
Examining psychedelic drug actionD Dewran Kocak, Bryan L Roth
JAMA Neurology|September 27, 2015
Chemogenetics-A Transformational and Translational PlatformJustin G English, Bryan L Roth
Schizophrenia Bulletin|July 10, 2007
Molecular targets for treating cognitive dysfunction in schizophreniaJohn A Gray, Bryan L Roth
Trends in Pharmacological Sciences|March 12, 2003
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptorDouglas J Sheffler, Bryan L Roth
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Hallucinogen actions on human brain revealedHyeong-Min Lee, Bryan L Roth
Pageof 45

Showing results (31-40 of 450) with videos related to

Sort By:
Pageof 45
Molecular Pharmacology|December 4, 2003
Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variantsVincent Setola, Bryan L Roth
The International Journal of Neuropsychopharmacology|December 19, 2014
DREADD: a chemogenetic GPCR signaling platformHu Zhu, Bryan L Roth
Biochemistry|September 5, 2018
Phosphoproteomics Illuminates Opioid ActionsTao Che, Bryan L Roth
Neuron|May 24, 2014
Silencing synapses with DREADDsHu Zhu, Bryan L Roth
Molecular Interventions|October 13, 2006
Salvinorin A: from natural product to human therapeuticsTimothy A Vortherms, Bryan L Roth
Nature Chemistry|January 5, 2024
Examining psychedelic drug actionD Dewran Kocak, Bryan L Roth
JAMA Neurology|September 27, 2015
Chemogenetics-A Transformational and Translational PlatformJustin G English, Bryan L Roth
Schizophrenia Bulletin|July 10, 2007
Molecular targets for treating cognitive dysfunction in schizophreniaJohn A Gray, Bryan L Roth
Trends in Pharmacological Sciences|March 12, 2003
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptorDouglas J Sheffler, Bryan L Roth
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Hallucinogen actions on human brain revealedHyeong-Min Lee, Bryan L Roth
Pageof 45